Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 8/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21960965 | 0.88 | MAP3K14 (0.35) | HCAR2MAP3K14KMT2AKLKB1TSHR | |
| SCHEMBL21960964 | 0.78 | MAP3K14 (0.35) | MAP3K14 | |
| SCHEMBL23880254 | 0.77 | MAP3K14 (0.35) | MAP3K14 | |
| SCHEMBL17437876 | 0.76 | ALKBH1 (0.36) | KMT2AKLKB1GAA | |
| SCHEMBL26133547 | 0.73 | KEAP1 (0.39) | KMT2A | |
| SCHEMBL21964592 | 0.71 | HCAR2 (0.37) | HCAR2MAP3K14MAPK1TSHR | |
| SCHEMBL20358174 | 0.71 | L3MBTL1 (0.38) | KMT2AMAPK1GAA | |
| SCHEMBL21723727 | 0.70 | KLKB1 (0.38) | KMT2AKLKB1MAPK1 | |
| SCHEMBL29333794 | 0.69 | EPHX2 (0.44) | MAP3K14KLKB1 | |
| SCHEMBL3847906 | 0.68 | L3MBTL1 (0.44) | HCAR2MAPK1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136311-B2 | Heteroaromatic derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-05 | — | — | US | disclosed |
| EP-3478675-B1 | HETEROAROMATIC DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136311-B2 | Heteroaromatic derivatives as NIK inhibitors | NFKBIA, IKBKG, IKBKE | HCAR2 1525/4885MAP3K14 4/4885KMT2A 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.